We have located links that may give you full text access.
Association of modified Nordic diet with cardiovascular risk factors among type 2 diabetes patients: a cross-sectional study.
Introduction: Cardiovascular disease (CVD) is one of the most important causes of mortality. Healthy diets can decrease CVDs and other chronic diseases especially in patients with type 2 diabetes. In this study, we investigate association between adherence to the modified Nordic diet and cardiovascular risk factors among patients with type 2 diabetes. Methods: This cross-sectional study was conducted among 339 type 2 diabetic patients. Anthropometric indices, blood pressure, and biochemical tests were evaluated. A validated and reliable semi-quantitative food frequency questionnaire (FFQ) was used to assess dietary intake. Nordic diet scores were calculated based on median intakes of six food groups. Results: Body mass index (BMI) was higher among participants who were in the lowest tertile of adherence to the Nordic diet ( P =0.006). There was a significant association between socioeconomic status (SES) and adherence to the Nordic diet ( P <0.0001). Participants who were in the top category of adherence to the diet had significantly lower levels of aspartate aminotransferase (AST) ( P <0.0001). There was a significant inverse association between adherence to the Nordic diet and low density lipoprotein (LDL) levels (odds ratio [OR]=0.29 95% CI: 0.09, 0.91, P =0.025), high systolic blood pressure (SBP) levels (OR=0.35 95% CI=0.17-0.74, P =0.015), and risk of obesity (OR=0.25 95% CI: 0.10, 0.63, P =0.03). Conclusion: Results suggest that adherence to the Nordic diet is associated with reductions in the prevalence of obesity, LDL levels and blood pressure among type 2 diabetic patients. However, additional studies are needed to confirm these findings.
Full text links
Trending Papers
A Personalized Approach to the Management of Congestion in Acute Heart Failure.Heart International 2023
Potential Mechanisms of the Protective Effects of the Cardiometabolic Drugs Type-2 Sodium-Glucose Transporter Inhibitors and Glucagon-like Peptide-1 Receptor Agonists in Heart Failure.International Journal of Molecular Sciences 2024 Februrary 21
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app